Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial

The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is poorly understood and therapeutic strategies are lacking. This study aimed to identify plasma proteins with pathophysiological relevance in HFpEF and with respect to spironolactone-induced effects. We assessed 92 biomar...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Moritz Schnelle, Andreas Leha, Abass Eidizadeh, Katharina Fuhlrott, Tobias D. Trippel, Djawid Hashemi, Karl Toischer, Rolf Wachter, Christoph Herrmann-Lingen, Gerd Hasenfuß, Burkert Pieske, Lutz Binder, Frank Edelmann
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2021-10-01
coleção:	Cells
Assuntos:	plasma biomarkers heart failure with preserved ejection fraction spironolactone
Acesso em linha:	https://www.mdpi.com/2073-4409/10/10/2796
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!